Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIMOC personalized targeted therapies for severe unclassified inflammatory multi-organ disease
2017-000519-18Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of secukinumab, adalimumab, anakinra, rituximab, tocilizumab and 1 more in undifferentiated autoinflammatory disease (uSAID) and dermatitis (6 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite response at month 6. Started Sep 2018; status: active.
02
Drugs
03
Conditions
undifferentiated autoinflammatory disease (uSAID)dermatitis
Beyond the preview
Go deeper on 2017-000519-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000519-18.